ulcerative colitis research hub

A Study to Learn How Different Manufactured Products of the Study Medicine Called Ritlecitinib are Taken up Into the Blood in Healthy Adults When Taken on an Empty Stomach or When Taken With a Meal in Healthy Adults.

This study looks at how a new medicine, ritlecitinib, gets into the blood of healthy adults. We're testing different versions of the medicine, both when taken on an empty stomach and with food. It could help people with conditions like ulcerative colitis or alopecia.

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis

This study is looking at a new medicine called Pimozide for rheumatoid arthritis. It aims to see if the medicine is safe, what side effects it might cause, and how it works in the body when given multiple times. This is a very early stage of research.

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

This study is looking into a new treatment called Imvotamab for people with moderate to severe rheumatoid arthritis. It's an early-stage study to understand how safe the treatment is and if it has any effects on the body.

I4V-MC-JAJA (RA-BRIDGE): A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

This study looks at how safe and effective a medicine called baricitinib is for people with rheumatoid arthritis, compared to other common treatments. It will see how long it takes for a blood clot to happen. This is a long-term study that will last over five years.

RCT part: CareRA2020: Effectiveness of a combination of Methotrexate and a step down glucocorticoid regimen (COBRA-Slim) for remission induction in patients with early Rheumatoid Arthritis (RA), with or without fast access to 24 weeks of Tumor Necrosis Factor (TNF) blockade in insufficient responders, a randomized, multicenter, pragmatic trial. LTE part: CareRA2020 LTE: a 3 year longitudinal observational, multicenter, follow-up of early RA patients after participation in the CareRA2020 RCT.

This study looks at how well a treatment for early rheumatoid arthritis (RA) works over a long time. It compares a standard approach with one that offers quicker access to a stronger medicine for those who aren't improving enough.

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety study of SAR441566 plus Methotrexate in Adults with Moderate to Severe Rheumatoid Arthritis

This study is testing a new medicine, SAR441566, for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. It aims to see if the new medicine helps reduce arthritis symptoms and if it's safe to use. Patients will either get the new medicine or a dummy medicine.

A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers

This early-stage study is looking at a new medicine called AZD1163 for rheumatoid arthritis. Researchers want to see if it's safe and how well healthy people tolerate it when given through a vein or under the skin. It’s the first time this medicine is being tested in humans.

A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13) added to disease-modifying antirheumatic drugs in patient with moderate to severe Rheumatoid Arthritis

This study is testing a new medicine, Burfiralimab, for people with moderate to severe rheumatoid arthritis. We want to see if it helps reduce joint pain and swelling when added to their usual arthritis medicines. Participants will receive either the new medicine or a dummy treatment.

A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

This study is comparing a new version of a rheumatoid arthritis medicine, called DRL_AB, with an existing one, Orencia. It aims to see if the new medicine works as well, is safe, and causes a similar immune response in people with moderate to severe rheumatoid arthritis.

MK-2420 SAD Study

This early-stage study is looking at a new medicine called MK-2420 for rheumatoid arthritis. It's the first time this medicine is being given to people, to check how safe it is and how the body handles it. Only adult men can take part.

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF IA-14069 IN HEALTHY SUBJECTS, WITH AN EXTENSION TO EXPLORE ANY DRUG-DRUG INTERACTION POTENTIAL WITH METHOTREXATE (PART 1), AND IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH PRELIMINARY ASSESSMENT OF EFFICACY IN PATIENTS (PART 2)

This study is testing a new medicine, IA-14069, for rheumatoid arthritis. It first checks if the medicine is safe and how it works in healthy people, then looks at its effects in people with rheumatoid arthritis.

A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

This study is looking at the long-term safety and effectiveness of a medicine called Jyseleca for people with rheumatoid arthritis. Participants will take Jyseleca tablets, and doctors will monitor their health carefully over time.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

This study is comparing two versions of a drug called upadacitinib. It's to check if a new version works the same way in the body as the existing one. Healthy adults volunteer for this study.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.

This study compares a new version of upadacitinib (a medicine for arthritis and other conditions) from Sun Pharma with the existing Rinvoq medicine. Doctors want to check if both versions work the same way in healthy adults after they’ve eaten.

An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

This study compares two versions of a 15mg upadacitinib tablet in healthy adults. It's to see if a new tablet works the same way in the body as an existing one, for conditions like rheumatoid arthritis and Crohn's disease.

A Prospective, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of MB04 and EU-sourced Enbrel® in Patients with Moderate to Severe Rheumatoid Arthritis.

This study is comparing a new medication called MB04 with a standard medicine, Enbrel, for people with moderate to severe rheumatoid arthritis. We want to see if MB04 works just as well and is as safe as Enbrel. This will help us understand if it's a good treatment option.

A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SPIRONOLACTONE FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) - ALDORA

This study, called ALDORA, is looking at whether a common medicine called spironolactone could help people with rheumatoid arthritis (RA). It’s comparing spironolactone to a dummy pill to see if it reduces RA symptoms and improves heart health without causing too many side effects.

A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

This study looks at different ways to treat early rheumatoid arthritis, comparing standard treatments with newer biologic medicines. It also explores if medicine doses can be lowered for people who are getting better, aiming to find the most effective and safe long-term approaches.

A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.

This study is testing a new tablet, AP1189, for people recently diagnosed with rheumatoid arthritis who haven't tried other strong medicines yet. It aims to see how well different doses of AP1189 lower inflammation and improve symptoms when taken with another common arthritis medicine.

A clinical study of MK-2420 in healthy men (MK-2420-003)

This study is looking into a new potential medicine, called MK-2420. It's being tested in healthy adult men to see how it works in the body and if it's safe. The goal is to find better ways to treat conditions like rheumatoid arthritis in the future.

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.

Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder System

This study looks at how well a new type of shoulder replacement, called the Trabecular Metal Reverse Shoulder System, works for people with severe shoulder problems. It aims to see how long it lasts, if it reduces pain, and improves movement.

A Study of AZD0120 in Autoimmune Diseases

This study is looking at a new treatment called AZD0120 for certain long-term conditions like systemic sclerosis, inflammatory muscle diseases, and severe rheumatoid arthritis. It's an early-stage study to see how safe the treatment is and if people can tolerate it.

Safety of Splenic Stimulation for RA

This study looks at a new device for people with rheumatoid arthritis (RA) who haven't found relief with other treatments. It will see if stimulating a nerve near the spleen is safe and helps reduce RA symptoms. Five people will have the device implanted for 12 weeks.

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

This study compares two treatments, abatacept and adalimumab, for adults with early, severe rheumatoid arthritis who haven't responded well to methotrexate. It aims to see which treatment is better at reducing arthritis symptoms and improving quality of life.

Comprehensive Segmental Revision System

This study looks at how well a special shoulder and elbow replacement system works for people with joint problems, arthritis, or after surgery for cancer or injuries. It will track patients for at least 10 years to understand their long-term outcomes and improve future treatments.

A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

This study is looking at a new medicine called CT-P13 for adults with moderate to severe rheumatoid arthritis. Researchers want to see if it helps reduce symptoms and is safe to use. Some people will get the new medicine, and others will get a dummy medicine to compare.

BC Study of G7 Cup and Compatible Femoral Stems

This study looks at how well a new hip replacement cup, called the G7 Acetabular System, works for people needing hip surgery due to joint problems like arthritis. It helps ensure new implants are safe and effective.

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

This study looks at a new treatment called AZD5492 for lupus, myositis, and rheumatoid arthritis. It checks how safe it is, how well the body handles it, and how it works in adults.

Zimmer POLAR Persona - TKA (EMEA Study)

This study looks at how well the Zimmer Persona knee replacement works for people with severe knee pain and disability. It tracks how long the implant lasts, its safety, and how much it improves patients' daily lives over several years.

Sidus(TM) Post Market Clinical Follow-up (PMCF) Study

This study looks at how well a new shoulder replacement, called Sidus Stem-Free Shoulder, works in patients with shoulder pain due to conditions like arthritis. Doctors will check its safety and how long it lasts, as well as pain relief and shoulder movement, over a long period.

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

This study is testing a new medicine, IMVT-1402, for adults with a type of rheumatoid arthritis that's been hard to treat. It checks if the medicine works and is safe compared to a dummy treatment.

Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)

This study looks at a new way to help people with rheumatoid arthritis who still have pain even after their inflammation is treated. It uses a technique called neurofeedback to see if it can reduce this specific type of pain, as well as helping with tiredness and sleep problems.

EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality

This study aims to understand why common medicines don't work the same for everyone in the UK, especially for people from different backgrounds. It will look at many health conditions, hoping to improve how we treat them and make healthcare fairer for all.

The Medacta International GMK Sphere Post-Marketing Surveillance Study

This study is checking how well a new knee replacement, called the GMK Sphere, works for people with arthritis. Doctors will follow patients after their surgery to see how they recover and if the new knee joint helps them get back to their daily lives.

The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?

This study looks for early signs of arthritis, especially rheumatoid arthritis, before people even have noticeable symptoms. By closely watching people who might be at risk, researchers hope to learn how to identify the condition earlier and potentially treat it sooner.

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

This study is looking into a new medication called Afimkibart for adults with moderate to severe rheumatoid arthritis. It's for those who haven't found enough relief from or can't take other common treatments. The aim is to see how well it works and if it's safe.

Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty

This study looks at how a new digital platform, Pheno4U, helps patients who have had total knee replacement surgery. It collects information about their recovery and how well their knee works.

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

This study is testing a new medicine, AZD1163, for people with rheumatoid arthritis (RA) who haven't found enough relief from other treatments. It aims to see if the new medicine is safe and helps reduce RA symptoms.

A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee

This study looks at a new type of knee replacement system, called Vanguard 360, for people with knee problems like arthritis. It aims to see if this new system helps people move better, reduces pain, and lasts a long time after surgery.

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

This study looks at how a medicine called filgotinib works for people with rheumatoid arthritis in everyday life. Researchers want to see if it makes a difference to symptoms, side effects, and how patients feel, simply by observing those already taking the medication.

Concentration guided dose reduction versus standard dosing in tocilizumab treated heumatoid arthritis patients:a randomised, international, multicenter, non-inferiority trial

This study compares two ways of giving tocilizumab for rheumatoid arthritis: adjusting the dose based on blood levels vs. standard dosing. We want to see if adjusting the dose works just as well and is safe, helping to find the best treatment plan for patients.

Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial

This study is testing different treatments for new rheumatoid arthritis to see which works best at getting people into remission quickly. It compares a steroid injection (Kenacort-A) with a newer tablet (Jyseleca) to find out how many people feel much better after three months.

A clinical study of MK-2420 in healthy people (MK-2420-002)

This study is testing a new medicine, MK-2420, in healthy adults. It's an early-stage study to understand how the medicine works in the body and if it's safe. While the medicine might eventually help people with rheumatoid arthritis, this study is about testing its basic effects.

Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response

This study looks at how the body's immune cells, called B cells, behave in diseases like lupus and rheumatoid arthritis. It compares them to B cells that react to a tetanus shot to understand more about these conditions.

DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMIDS) USING SYSTEMS APPROACHES

This study looks at a new medicine called Tyenne for people with Psoriatic Arthritis or Rheumatoid Arthritis. It wants to see if this medicine helps reduce symptoms and if combining it with other treatments works better to put the disease into remission.

Non-inferiority study of TOCILIZUMAB in dose-banding versus dose-weight in rheumatoid arthritis with low activity or clinical remission

This study looks at a different way to give RoActemra (tocilizumab) for rheumatoid arthritis. We want to see if giving a standard dose based on how well you're doing, rather than your weight, works just as well for patients with low disease activity or who are in remission.

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

This study is testing a new medicine, AZD1163, for people with moderate to severe rheumatoid arthritis. We want to see if it helps reduce joint pain and swelling, and if it's safe to use. Half the participants will receive the new medicine and half will receive a dummy medicine.